WeightControl.com Interview with:
Xiaoying Li, MD
Professor and Director
Ying Chen, MD
Associate Professor
Department of Endocrinology and Metabolism
Zhongshan Hospital, Fudan University
Shanghai 200032 China
WeightControl.com: What is the background for this study?
Response: Overweight and obesity affect more than 50% of the population in China. In the SUROMOUNT-CN study, we have reported that the GIP/GLP-1 RA, tirzepatide led to a substantial weight loss of 14.4% and 19.9% by 10 mg and 15 mg treatment for 52 weeks, respectively, in overweight or obese Chinese adults. This observational study further evaluated weight loss maintenance following tirzepatide discontinuation.
Last Updated on August 2, 2025 by weightcontrol